These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34915346)

  • 21. Receptor pharmacophore ensemble (REPHARMBLE): a probabilistic pharmacophore modeling approach using multiple protein-ligand complexes.
    Kumar SP
    J Mol Model; 2018 Sep; 24(10):282. PubMed ID: 30220049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for Virtual Screening of GPCR Targets: Approaches and Challenges.
    Cross JB
    Methods Mol Biol; 2018; 1705():233-264. PubMed ID: 29188566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The structure of active opsin as a basis for identification of GPCR agonists by dynamic homology modelling and virtual screening assays.
    Schneider M; Wolf S; Schlitter J; Gerwert K
    FEBS Lett; 2011 Nov; 585(22):3587-92. PubMed ID: 22027616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening.
    Sato M; Hirokawa T
    J Chem Inf Model; 2014 Nov; 54(11):3153-61. PubMed ID: 25350693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel approach for efficient pharmacophore-based virtual screening: method and applications.
    Dror O; Schneidman-Duhovny D; Inbar Y; Nussinov R; Wolfson HJ
    J Chem Inf Model; 2009 Oct; 49(10):2333-43. PubMed ID: 19803502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling G protein-coupled receptors and their interactions with ligands.
    Costanzi S
    Curr Opin Struct Biol; 2013 Apr; 23(2):185-90. PubMed ID: 23415855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Structural Framework for GPCR Chemogenomics: What's In a Residue Number?
    Vass M; Kooistra AJ; Verhoeven S; Gloriam D; de Esch IJP; de Graaf C
    Methods Mol Biol; 2018; 1705():73-113. PubMed ID: 29188559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selection and design of GPCR ligands: from concept to the clinic.
    Ashton M; Charlton MH; Schwarz MK; Thomas RJ; Whittaker M
    Comb Chem High Throughput Screen; 2004 Aug; 7(5):441-52. PubMed ID: 15320711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.
    Kooistra AJ; Kuhne S; de Esch IJ; Leurs R; de Graaf C
    Br J Pharmacol; 2013 Sep; 170(1):101-26. PubMed ID: 23713847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects.
    Klabunde T; Evers A
    Chembiochem; 2005 May; 6(5):876-89. PubMed ID: 15791686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtual Screening of Human Class-A GPCRs Using Ligand Profiles Built on Multiple Ligand-Receptor Interactions.
    Chan WKB; Zhang Y
    J Mol Biol; 2020 Aug; 432(17):4872-4890. PubMed ID: 32652079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficiency of Homology Modeling Assisted Molecular Docking in G-protein Coupled Receptors.
    Bhunia SS; Saxena AK
    Curr Top Med Chem; 2021; 21(4):269-294. PubMed ID: 32901584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.
    Vilar S; Ferino G; Phatak SS; Berk B; Cavasotto CN; Costanzi S
    J Mol Graph Model; 2011 Feb; 29(5):614-23. PubMed ID: 21146435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complementarity of delta opioid ligand pharmacophore and receptor models.
    Mosberg HI
    Biopolymers; 1999; 51(6):426-39. PubMed ID: 10797231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray structure breakthroughs in the GPCR transmembrane region.
    Topiol S; Sabio M
    Biochem Pharmacol; 2009 Jul; 78(1):11-20. PubMed ID: 19447219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation.
    Bhattacharya S; Hall SE; Li H; Vaidehi N
    Biophys J; 2008 Mar; 94(6):2027-42. PubMed ID: 18065472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists.
    Du L; Li M
    Curr Comput Aided Drug Des; 2010 Sep; 6(3):165-78. PubMed ID: 20412040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug design strategies for targeting G-protein-coupled receptors.
    Klabunde T; Hessler G
    Chembiochem; 2002 Oct; 3(10):928-44. PubMed ID: 12362358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From three-dimensional GPCR structure to rational ligand discovery.
    Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
    Adv Exp Med Biol; 2014; 796():129-57. PubMed ID: 24158804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GLASS: a comprehensive database for experimentally validated GPCR-ligand associations.
    Chan WK; Zhang H; Yang J; Brender JR; Hur J; Özgür A; Zhang Y
    Bioinformatics; 2015 Sep; 31(18):3035-42. PubMed ID: 25971743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.